Clinical Trial Update: An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED) [Phase 3]

View source ↗

Summary

Phase 3 trial update for VRDN-003 in active thyroid eye disease (TED) focusing on efficacy, safety, and tolerability.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thyroid Eye Disease

Drugs mentioned

• VRDN-003

Snippet

Sponsor: Viridian Therapeutics, Inc. | Conditions: Thyroid Eye Disease | Phase 3 | Status: ACTIVE_NOT_RECRUITING